12:00 AM
Oct 09, 2006
 |  BioCentury  |  Politics, Policy & Law

Biomarkers PPP: An open book

Open, free access to intellectual property is the default position for projects conducted by the public-private Biomarkers Consortium launched last week.

Unless they can convince the consortium's executive committee that there is a compelling need for IP protection, institutions and companies will have to grant other participants in biomarker projects free access to IP they bring to a project, as well as to IP developed by the project. They also will be required to grant non-exclusive, remuneration-free research licenses to other parties for products developed through the projects.

The consortium, which is operating under the auspices of the Foundation for the NIH (FNIH), is an effort to combine the resources of government, represented by NIH, FDA and CMS, with those of the pharmaceutical, biotech, diagnostics and medical device industries and non-profit organizations to discover and validate biomarkers. It is a major step down both FDA's Critical Path and NIH's Roadmap,...

Read the full 733 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >